The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Cited by (426)

Items 301–400 of 426

1. Deconjugating taurocholic acid with Bifidobacterium to mitigate obesity-driven cancer progression by restoring CD8+ T-cell infiltration
   Ruoshui Yuan, Yuke Li, Yifei Wang, Qingxiang Li, Chuanbin Guo, Lin Wang · 2025 · npj Biofilms and Microbiomes
2. Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD
   Yan Huang, Jiaqi Li, Shuying Song, Bingying Du, Yutang Cao, Yangyang Wang, Haoshuang Fu, Tianhui Zhou, Shuwu Yu, Yameng Liu et al. · 2025 · Cell Reports Medicine
3. Dietary bile acids alleviate corticosterone-induced fatty liver and hepatic glucocorticoid receptor suppression in broiler chickens
   Jie Liu, Ke Zhang, Mindie Zhao, Liang Chen, Huimin Chen, Yulan Zhao, Ruqian Zhao · 2024 · Journal of Animal Science
4. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet
   Eugenia Carril, M. Pilar Valdecantos, Borja Lanzón, Santiago Angulo, Ángela M. Valverde, Joanna Godzień, Francisco Javier Rupérez · 2019 · Journal of Pharmaceutical and Biomedical Analysis
5. Characterization of endogenous bile acid composition in individuals with cold-activated brown adipose tissue
   Carsten Thilo Herz, Oana Cristina Kulterer, Marlene Prager, Felix Benedikt Langer, Gerhard Prager, Rodrig Marculescu, Günter Fauler, Marcus Hacker, Alexandra Kautzky‐Willer, Michael A Trauner et al. · 2021 · Molecular and Cellular Endocrinology
6. Molecular and Metabolic Phenotyping of Hepatocellular Carcinoma for Biomarker Discovery: A Meta-Analysis
   Nguyễn Hoàng Anh, Nguyen Phuoc Long, Young Jin Min, Yujin Ki, Sun Jo Kim, Cheol Woon Jung, Seongoh Park, Sung Won Kwon, Seul Ji Lee · 2023 · Metabolites
7. FXR adapts hepatic mitochondrial function to increased substrate oxidation in patients with obesity
   Katrin Panzitt, Emilian Jungwirth, L E Vosko, Corina T. Madreiter‐Sokolowski, Tobias Madl, Ines Tawfik, Hansjörg Habisch, Jelena Krstić, Andreas Prokesch, Robert Karitnig et al. · 2025 · Science Translational Medicine
8. A critical review of natural products driven correction of bile acid dysregulation: a therapeutic strategy for nonalcoholic fatty liver disease
   Qing Peng, Liyuan Hao, Shenghao Li, Fei Yu, Na Li, Xiaoyu Hu · 2025 · Frontiers in Pharmacology
9. Pleiotropic immunoregulation by bile acids in pathophysiology
   Bo-Shen Lin, Minyue Yin, Si-An Xie, Peng Li, Xue Li · 2026 · Frontiers in Immunology
10. A review in two classes of hypoglycemic compounds (prebiotics and flavonoids) intervening in type 2 diabetes mellitus: Unveiling their structural characteristics and gut microbiome as key mediator
    Zerun Li, Tingting Zhang, Yang Liu, Yanhong Huang, Jianjun Liu, Shanshan Wang, Ping Sun, Yupeng Nie, Yanlei Han, Fanghua Li et al. · 2024 · Food Bioscience
11. Role of cholesterol homeostasis in MASH-driven hepatocellular carcinoma: not just a neutral fat
    Vicent Ribas · 2024 · Exploration of Digestive Diseases
12. Unique metabolomics characteristics for distinguishing cirrhosis related to different liver diseases: A systematic review and meta-analysis
    Liu Yang, Fang Wang, Sijia Liu, Zicheng Xian, Shenshen Yang, Yanyan Xu, Lexin Shu, Xingxu Yan, Junjie He, Xia Li et al. · 2024 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
13. Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease
    Ashraf Abbass Basuni, Dina Sweed, Mohamed Fathey Elgazzar, Ashraf A. Khalil · 2024 · Egyptian Liver Journal
14. Pharmacological effects of bile acids on polycystic ovary syndrome via the regulation of chemerin
    Tian‐Tian Tong, Long‐Bo Bai, Lee‐Fong Yau, Jiu-Yan Li, Hao Huang, Zhi‐Hong Jiang · 2025 · Chinese Medicine
15. Huaganjian decoction ameliorates metabolic dysfunction-associated steatotic liver disease through liver-gut crosstalk
    Qin Dong, Yang Wang, Yuxin He, Tianhui Gao, Ling Li, Liping Chen, Chuan Liu, Wenyu Wang, Xiao Liu, Yuyu Zhang et al. · 2025 · Journal of Ethnopharmacology
16. Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis
    Marion Pradeau, Sandrine Beaulieu, Véronique Paquet, Jocelyn Trottier, Mélanie Verreault, Stéphanie Ferland, Olivier Barbier, Anne‐Marie Carreau · 2025 · American Journal of Physiology-Endocrinology and Metabolism
17. Gut microbiota drives the metabolic dysregulation in obesity-prone individuals by impairing GDCA-mediated activation of brown adipose thermogenesis and ileal GLP-1 secretion
    Han Ma, Yuqi Wu, Delong Li, Haowen Sun, Yuan Xie, Shichun Zhao, Wenqian Guo, Meng Wang, Renyun Cui, Yanrong Huang et al. · 2025 · Acta Pharmaceutica Sinica B
18. Free fatty acids induce bile acids overproduction and oxidative damage of bovine hepatocytes via inhibiting FXR/SHP signaling
    Zhiyuan Fang, Zhiru Zhou, Lingxue Ju, Qi Shao, XU Yong-wei, Yuxiang Song, Wenwen Gao, Lin Lei, Guowen Liu, Xiliang Du et al. · 2024 · The Journal of Steroid Biochemistry and Molecular Biology
19. Integrative analysis of non12‐hydroxylated bile acid revealed the suppressed molecular map of alternative pathway in nonalcoholic steatohepatitis mice
    Yanruyu Feng, Chang‐Hai Liu, Jingtao Yang, He Zhang, Lian Li, Qian Yang, Wei Gan, Zi Yang, Puyang Gong, Chunmei Fu et al. · 2024 · The FASEB Journal
20. Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
    Ying Geng, Yi-Fang Li, Ge Liu, Jian Jiao · 2024 · Scientific Reports
21. Mitochondrial targeted therapies in MAFLD
    Sien Lai, Dongsheng Tang, Juan Feng · 2025 · Biochemical and Biophysical Research Communications
22. RETRACTED: The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
    Lucia Carulli, Giulia Zanca, Filippo Schepis, Erica Villa · 2019 · Metabolites · Retracted
23. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation
    Marta Alonso‐Peña, Ricardo A. Espinosa-Escudero, Heike M. Hermanns, Óscar Briz, José M. Herranz, Carmen García‐Ruiz, José C. Fernández-Checa, Javier Juampérez, Matias Antonio Avila, Josepmaria Argemí et al. · 2022 · Cells
24. Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
    Roman Vyacheslavovich Maslennikov, Yu. V. Evsyutina · 2018 · Russian Journal of Gastroenterology Hepatology Coloproctology
25. Dysregulated bile acid metabolism drives lipid peroxidation and ferroptosis in NAFLD: therapeutic potential for traditional Chinese medicine
    Jing Liu, Fuxing Li, Qianru Zeng, Wenxiao Hu, Le Yang, Shengping Luo, Dingxiang Li, Yihui Deng · 2025 · Frontiers in Pharmacology
26. A Deep Multimodal Fusion Framework Integrating SERS, Clinical Data, and Metabolomics for Noninvasive MASH Diagnosis
    Weilin Wu, Dechan Lu, Yan Ni, Zufang Huang, Ming-Hua Zheng, Jing Wang · 2026 · Analytical Chemistry
27. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
    May G. Akl, Scott B. Widenmaier · 2023 · Frontiers in Cell and Developmental Biology
28. Chenodeoxycholic acid regulates fibroblast growth factor 23 gene expression via estrogen-related receptor γ in human hepatoma Huh7 cells
    Yiwen Fan, Hyo‐Jin Kim, Yoon Seok Jung, Soon‐Young Na, Kamalakannan Radhakrishnan, Hueng‐Sik Choi · 2023 · Steroids
29. Hyocholic acid: A novel therapeutic strategy for metabolic syndrome
    Bohan Rong, Qian Zhang, Xiaohan Zhang, Na Zhang, Zhentong Shen, Yu Pang, Xu Kevin Lin, Di Liu, Xiuqin Yang · 2024 · The Innovation Life
30. État des lieux sur la physiopathologie, le diagnostic et les traitements de la stéato-hépatite non alcoolique (NASH)
    Guillaume Grzych, L. Bernard, R. Lestrelin, Anne Tailleux, Bart Staels · 2022 · Annales Pharmaceutiques Françaises
31. Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form
    Alan Frederick Hofmann, Hanns–Ulrich Marschall · 2018 · Hepatology
32. Anti-Dyslipidemic, Anti-Hypertensive, and Glycemic Control Effects of Akkermansia Muciniphila: Lesser-Known Benefits in Metabolic Syndrome – A Narrative Review
    Amirmohammad Abolhassani, Mohammed H. Moghadasian, Niloofar Sedaghatnezhad, Sadegh Jafarnejad · 2025 · Heart and Mind
33. Conjugated bile acids in serum reflect disease severity and predict survival in chronic liver disease of humans and rats
    Akiko Eguchi, Motoh Iwasa, Teruo Miyazaki, Mina Tempaku, Masako Ichishi, Yasuyuki Tamai, Ryuta Shigefuku, Yoshinao Kobayashi, Akira Honda, Masatoshi Watanabe et al. · 2025 · Scientific Reports
34. Intestine-derived fibroblast growth factor 19 alleviates lipopolysaccharide-induced liver injury by regulating bile acid homeostasis and directly improving oxidative stress
    Xiaomeng Tang, Jingjing Ning, Yilin Zhao, Shuyun Feng, Lujing Shao, Tiantian Liu, Huijie Miao, Yucai Zhang, Chunxia Wang · 2024 · Journal of Intensive Medicine
35. Evaluation of FXR Activity in Pollutants Identified in Sewage Sludge and Subsequent in Vitro and in Vivo Characterization of Metabolic Effects of Triphenyl Phosphate
    Yi Yang, Ling Jiao, Yixuan Huang, Hailin Shang, Enrui Li, Hong Chang, Hongyang Cui, Yi Wan · 2025 · Environmental Health Perspectives
36. Pre-diagnostic circulating bile acid concentrations and liver cancer risk: a nested case-control analysis of 12 cohorts
    Cody Z. Watling, Jessica L. Petrick, Barry I. Graubard, Xuehong Zhang, Matthew J Barnett, Julie E. Buring, Yu Chen, A. Heather Eliassen, J. Michael Gaziano, Jonathan N. Hofmann et al. · 2025 · JNCI Cancer Spectrum
37. Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma
    Minami Yamauchi, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Mio Tsuruoka, Jun Inoue, Atsushi Masamune, Nariyasu Mano · 2024 · Metabolites
38. Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques
    Michael J. Nash, Evgenia Dobrinskikh, Saif I. Al‐Juboori, Rachel C. Janssen, Jolyn Fernandes, Amy Argabright, Angelo D’Alessandro, Melissa Ann Kirigiti, Paul Kievit, Kjersti Marie Aagaard et al. · 2025 · Liver International
39. Clinical application of bile acid profile combined with lipid indices in metabolic dysfunction-associated steatotic liver disease
    Zhenhua Liu, Hongwei Gao, Wen Yan, Simin Li, Wenwen Jiang, Yingying Wang, Yao Jiang, Chongge You · 2025 · Clinica Chimica Acta
40. Serum Glycocholic Acid‐to‐Total Bile Acid Ratio Is Independently Associated with Nonalcoholic Fatty Liver Disease: A Retrospective Cross‐Sectional Study
    Li Hu, Jin Ma, Leilei Gu, Peizhan Chen, Li Chen, Xinxin Zhang · 2021 · BioMed Research International
41. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis
    Yang Zhang, Junxiang Li, Yan Zhang, Yunliang Wang · 2021 · World Journal of Clinical Cases
42. Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD
    Natalie Eppler, Elizabeth Jones, Forkan Ahamed, Yuxia Zhang · 2025 · Livers
43. Tryptophan derivatives as non‐invasive diagnostic indicators for obesity‐related MASLD in children and adolescents
    Shumin Zhan, Xingyun Wang, Chen Wang, Bowen Zhu, Jianfang Gao, Zhou Peng, Rui Wang, Yun Yang, Liang Zhang, Tengfei Wang et al. · 2025 · Diabetes Obesity and Metabolism
44. The role of FGF19–FGFR4 signaling pathway in liver health and disease: Guardian or destroyer
    Zhangfan Wu, Yijun Wang, Jiaqian Zhang, Siwen Li, Junjie Wen, Dian Hu, Junqing Jiang, Zerui Zhang, Xiangyuan Luo, Limin Xia · 2025 · Genes & Diseases
45. Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis
    Jaclyn A. Rivas, Alexandria C. Murphy, Praveena Prasad, Mahmoud S. Yahia, Siem S. Goitom, Aaron S. Romero, Crystal Madera Enriquez, Brianna B. Maes, Prithvi Reddy Akepati, Marcus A. Garcia et al. · 2026 · Metabolism
46. Effect of Ilex hainanensis Merr. On HFD-induced nonalcoholic fatty liver disease and rebalance of gut microbiota and bile acids metabolism in mice
    Jia-yi Tian, Xiao Meng, Wenwen Zhao, Xia Wu, Jie Yang, Xiao-qing Chen · 2024 · Fitoterapia
47. Comparison of Liver Bile Acid Profiles in Chronic Alcohol Feeding and Niaaa Binge‐On‐Chronic Alcohol Feeding Mouse Models
    Jing Feng, Liqing He, Xipeng Ma, Xinmin Yin, Eugene G. Mueller, Zhanxiang Zhou, Wenke Feng, Craig James McClain, Xiang Zhang · 2025 · Journal of Chromatography B
48. E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p
    Maider Apodaka-Biguri, A. Simão, Francisco González-Romero, Daniela Mestre, Pedro M. Rodrigues, Igor Aurrekoetxea, Beatriz Gómez-Santos, Xabier Buqué, Ane Nieva-Zuluaga, Mikel Ruiz de Gauna et al. · 2025 · Hepatology
49. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis
    David J. Matye, Xuan Qin, Mohammad Nazmul Hasan, Lijie Gu, Yung Dai Clayton, Feng Li, Tiangang Li · 2022 · Liver Research
50. Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
    Michihiro Iwaki, Takaomi Kessoku, Kosuke Tanaka, Anna Ozaki, Yuki Kasai, Takashi Kobayashi, Asako Nogami, Yasushi Honda, Yuji Ogawa, Kento Imajo et al. · 2023 · Hepatology Communications
51. Longitudinal serum total bile acid trajectories and risk of metabolic dysfunction-associated fatty liver disease: a retrospective cohort study
    Huihui Chen, Xinyan Yu, Xueni Wang, Jiaojiao Huang, Jingni Wu, Xinmei Zhou, Kejia Hu, Zhenya Song · 2025 · European journal of medical research
52. Integration of Pseudotargeted Metabolomics and Microbiomics Reveals That Hugan Tablets Ameliorate NASH with Liver Fibrosis in Mice by Modulating Bile Acid Metabolism via the Gut Microbiome
    Wenran Dong, Ying Wang, Huajinzi Li, Hongxia Ma, Yingxi Gong, Gan Luo, Xiaoyan Gao · 2025 · Metabolites
53. Gut microbes mediate the synergistic effects of dietary cholesterol and saturated fat in driving fibrosing MASH
    Jake B. Hermanson, Samar A. Tolba, Md. Amran Gazi, Evan A. Chrisler, Manpreet Kaur, Ashley M. Sidebottom, Yong-Jun Liu, Guillermo Martinez Boggio, Lauren N. Lucas, Daniel Amador‐Noguez et al. · 2026 · Gut Microbes
54. Towards the clinical use of peripheral bile acids: Recommendations to limit their preanalytical and analytical sources of variability
    Sebastian Joseph, Sophie de Buyl, Isabelle A. Leclercq, Kristian Serafimov, Olivier Féron, Laure‐Alix Clerbaux · 2025 · Practical Laboratory Medicine
55. Serum bile acid profiles in pediatric gastrointestinal, hepatic and biliary diseases
    Katja Linz, Felix Wachter, Merle Claßen, Jakob Zierk, Theresa Voggenreiter, Alexander Schnell, Henriette Mandelbaum, Joachim Woelfle, Ferdinand Knieling, André Hoerning et al. · 2025 · Molecular and Cellular Pediatrics
56. Pharmacology of NASH
    Somaya A. M. Albhaisi, Arun Jayant Sanyal · 2021 · Elsevier eBooks
57. DOENÇA HEPÁTICA GORDUROSA NÃO ALCOÓLICA: ATUALIZAÇÃO SOBRE A FISIOPALOGIA
    Débora Gonçalves da Silva, Josué da Silva Brito, Beatriz Francisco Barbosa Rodrigues, Daniele Martins Afonso, Angélica Amorim Amato · 2015 · Brasília Médica
58. RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
    Yanyan Wang, Yunling Tai, Grayson W. Way, Jing Zeng, Derrick Zhao, Lianyong Su, Xixian Jiang, Xuan Wang, Emily C. Gurley, Jinze Liu et al. · 2022 · Research Square
59. The importance of bile Acids in NAFLD: current evidence and future directions
    Alvaro Rivera‐Andrade, Christian S. Álvarez · 2022 · Annals of Hepatology
60. Analysis of Serum Bile Acid Profile Characteristics and Identification of New Biomarkers in Lean Metabolic Dysfunction-Associated Fatty Liver Disease Based on LC-MS/MS
    Bing Wang, Fei Zhang, Hong Qiu, Yu He, Haotian Shi, Yuerong Zhu · 2024 · Clinical Medicine Insights Endocrinology and Diabetes
61. Clinical Features and Plasma Metabolites Analysis in Obese Chinese Children With Nonalcoholic Fatty Liver Disease
    Xiaoxiao Liu, Shifeng Ma, Jing Li, Mingkun Song, Yun Li, Yingyi Qi, Fei Liu, Zhongze Fang, Rongxiu Zheng · 2025 · Journal of the Endocrine Society
62. ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress
    Yuanzhen Zhang, Xiaozhi Hu, Zhonglian Cao, Kaicheng Zhou, Yun Sun, Yong Deng, Shuwen Xu, Yanyang Nan, Xi Gai, Mengyang Li et al. · 2025 · International Journal of Biological Macromolecules
63. Mutation of PXR phosphorylation motif at Ser347 disrupts lipid and bile acid homeostasis in diet-induced metabolic dysfunction–associated steatohepatitis in mice
    Veronia Basaly, Zakiyah R Henry, Rulaiha E. Taylor, Bo Kong, Ill Yang, Anita Brinker, Zhenning Yang, Peihong Zhou, Laurie B. Joseph, Lauren M. Aleksunes et al. · 2025 · Drug Metabolism and Disposition
64. Integrated metabolomics and machine learning identify potential biomarkers and metabolism-related targets for MASLD in older adults
    Ze Jin, Mengpei Zhu, Ziwen Wang, Lina Xiong, Zhifan Xiong · 2026 · Experimental Gerontology
65. Bile acid-mediated regulation of pyroptosis in PCOS: a hypothesis for hepato-ovarian axis
    Sukran Yagmur Avcioglu, Çağlar Berkel · 2026 · Comparative Clinical Pathology
66. Arid1a deficiency promotes metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma by disrupting the FXR-gut microbiota-bile acid axis
    Shu‐Jin Song, Lan Wang, Li Li, Shi-Hao Bai, Xin‐Le Zhu, Xiao-Li Zhang, Chuan-Huai Deng, Ze‐Guang Han · 2026 · Cancer Letters
67. Role of the gut microbiota–bile acid axis in liver fibrosis based on microbiomics and targeted metabolomics
    Yu-Lin Zhang, Hong-Zhong Gou, Zhen-Jiao Li, Jia-Hui Xi, Xiao-Juan Wang, Jin Shang, Dan Zhu, Longfei Ren, Xiao-Jun Shu, Lei Zhang (38117) · 2026 · BMC Microbiology
68. The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications
    Wei Zheng, Qian Feng, Juan Wang, X X Li, Shuo Yin · 2026 · Frontiers in Physiology
69. How Our Understanding of the Microbiome Has Changed the Way We Look at Liver Diseases
    Timon Erik Adolph, Maria Effenberger, Herbert Tilg · 2018 · Biomarkers in Medicine
70. Pleiotropic effects of ursodeoxycholic acid in patients with non-alcoholic steatohepatitis with impaired glycemic control
    A. A. Shipovskaya, Курбатова Ирина Валерьевна, Ольга Петровна Дуданова · 2020 · Экспериментальная и клиническая гастроэнтерология
71. Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma
    Yue Chen, Yutao Wang, Lei Jin, Bowen Chen, Xinfeng Zhang, Liangzheng Chang, Zhangli Hu, Yun Wang, Yinying Lu · 2024 · Frontiers in Pharmacology
72. Pharmacotherapy of Non-Alcoholic Fatty Liver Disease: Updated Data
    Л. В. Тарасова, Yu. V. Tsyganova, Irina V. Opalinskaya, Т. Е. Степашина · 2020 · Effective Pharmacotherapy
73. The role of integrin alpha 7 in diet-induced obesity and signalling
    Jamie Taylor · 2018 · UEA Digital Repository (University of East Anglia)
74. Norcholic acid: a novel biomarker of early kidney injury in patients with metabolic dysfunction-associated fatty liver disease
    Dan‐Qin Sun, Cuifang Xu, Wen‐Ying Chen, Fuqiang Yuan, Giovanni Targher, Amedeo Lonardo, Jing Zhao, Ana Liu, Mingming Su, Junping Shi et al. · 2023 · Research Square
75. Investigations of 12α-Hydroxylated Bile Acid Signaling in Intestinal Organoids
    Tiara R. Ahmad · 2019
76. Role of non-alcoholic fatty liver disease in development of cardiovascular disease
    Zheng-Yu Tao, Jing Zeng · 2022 · World Chinese Journal of Digestology
77. Abstracts
    Marc Bourlière, Stanislas Pol · 2019 · Liver International
78. Non-alcoholic fatty liver disease in the context of the gut microbiome
    Oleksiy Gridnyev, К.Ю. Дубров · 2019 · Modern Gastroenterology
79. Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
    Yufang Ding, Karin Yanagi, Fang Yang, Evelyn S. Callaway, Clint Cheng, Martha E. Hensel, Rani Menon, Robert Christopher Alaniz, Kyongbum Lee, Arul Jayaraman · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
80. Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice
    Yufang Ding, Karin Yanagi, Fang Yang, Evelyn S. Callaway, Clint Cheng, Martha E. Hensel, Rani Menon, Robert Christopher Alaniz, Kyongbum Lee, Arul Jayaraman · 2023 · eLife
81. Reviewer #1 (Public Review): Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice
    2023 · eLife
82. Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
    Yufang Ding, Karin Yanagi, Fang Yang, Evelyn S. Callaway, Clint Cheng, Martha E. Hensel, Rani Menon, Robert Christopher Alaniz, Kyongbum Lee, Arul Jayaraman · 2023 · eLife
83. Mechanism for FXR to regulate bile acid and glycolipid metabolism to improve NAFLD
    Zhi Guo Huang, Rongrong Zhou · 2023 · World Chinese Journal of Digestology
84. Integrative proteomics and metabolomics explore the effect and mechanism of Qiyin granules on improving nonalcoholic fatty liver disease
    Xuehua Yan, Hongbing Liu, Meng Huang, Yujie Zhang, Binfang Zeng · 2024 · Heliyon
85. The Modulation of Gut Microbiota by Bariatric Metabolic Surgery and Its Role in NAFLD Treatment
    小磊 郝 · 2024 · Advances in Clinical Medicine
86. The Role of the Intestinal Microbiota in NAFLD Onset and Progression
    Iris Pinheiro · 2024 · IntechOpen eBooks
87. Biological, experimental and analytical determinants influencing bile acids concentrations in human blood: a review and meta-analysis
    Sebastian Joseph, Sophie de Buyl, Isabelle A. Leclercq, Laure‐Alix Clerbaux · 2025 · medRxiv
88. Extracellular vesicles from immortalised human amniotic epithelial cells reduce hepatic fibrosis in mice with Steatohepatitis and Hepatocellular Carcinoma
    Mihiri Goonetilleke, Jeanne Correia, Yuan Chen, Hannah McDonald, Siow Teng Chan, Ishmael M. Inocencio, Jonathon Cross, David W. Greening, Ian A. Simpson, William Sievert et al. · 2025 · Research Square
89. Exploration of Early Diagnostic Biomarkers for Intestinal Barrier Dysfunction in Non-Alcoholic Fatty Liver Disease
    庄巍 李 · 2025 · Advances in Clinical Medicine
90. Metabolomic, Lipidomic, and Enterohormone Changes in the Progression from MASLD to MASH
    Jaclyn A. Rivas, Alexandria C. Murphy, Praveena Prasad, Siem S. Goitom, Aaron S. Romero, Crystal Madera Enriquez, Brianna B. Maes, Prithvi Reddy Akepati, Marcus A. Garcia, Fredine T. Lauer et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
91. Enhanced nuclear localization of small heterodimer partner in metabolic dysfunction-associated steatohepatitis
    Shih-Chieh Chien, Chiung‐Yu Chen, Hung‐Wen Tsai, Yih‐Jyh Lin, Shu‐Chu Shiesh, Pin‐Nan Cheng, Hung‐Chih Chiu, Yen‐Cheng Chiu, Ya-Han Lin, Min-Shan Wu et al. · 2025 · JHEP Reports
92. Loss of hepatic alpha-1b adrenoceptor exacerbates inflammation and stellate cell activation in diet-induced MASLD
    Bernie Efole, Sarra Beji, Mathilde Mouchiroud, Yves Gélinas, Coraline Canivet, Jocelyn Trottier, Cindy Serdjebi, Joel Keith Elmquist, Jessica Deslauriers, Olivier Barbier et al. · 2025 · American Journal of Physiology-Gastrointestinal and Liver Physiology
93. Intestinal Epithelial Cell-derived Osteopontin Protects Against Metabolic Dysfunction–associated Steatohepatitis by Modulating Bile Acid Composition and the Gut Microbiome
    Hui Han, Jeongwoo Park, Rui Zhang, Nithyananthan Subramaniyam, Sukanta Das, Xiaodong Ge, Sai Santosh Babu Komakula, Chao Wang, Romain Désert, Wei Chen et al. · 2025 · Cellular and Molecular Gastroenterology and Hepatology
94. Hepatic insulin resistance is the basis of bile acid dysmetabolism in metabolic dysfunction-associated steatotic liver disease
    Sami U. Qadri, Joel T. Haas, Sirkku E. Jäntti, Kimmo Porthan, Anne Juuti, Anne K. Penttilä, Johanna Arola, Emilia Vartiainen, Eveline Lia Dirinck, Luisa Vonghia et al. · 2025 · medRxiv
95. Additional file 1 of Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora
    Miao, Xiaolei, Luo, Ping, Jiao Liu, Wang, Junjun, Chen, Yong · 2023 · Figshare
96. Additional file 1 of RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
    Wang, Yanyan, Tai, Yun-Ling, Grayson W. Way, Zeng, Jing, Derrick Zhao, Lianyong Su, Xixian Jiang, Jackson, Kaitlyn G., Wang, Xuan, Emily C. Gurley et al. · 2022 · Figshare
97. The role of bile acid dynamics in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease
    Si-Rui Yu, Run Sun, Mei-Ya Shi, Mei Yang, Kun Chen, Qiong Pan, Ling Zhao, Ming-Yue Wu, Jin Chai · 2026 · Liver Research
98. 10-hydroxy-2(E)-decenoic acid attenuates metabolic dysfunction–associated steatotic liver disease via modulation of the gut microbiota–bile acid–FXR axis
    Xinyu Yu, Meifei Zhu, Kangli Wang, Bin Yuan, Yuanyuan Lu, Shanshan Li, Fuliang Hu · 2026 · Food Bioscience
99. Precision medicine in steatotic liver disease
    Vitchapong Prasitsumrit, Vincent Lingzhi Chen · 2026 · Current Opinion in Gastroenterology
100. Primary, Secondary and Exploratory Endpoints in Phase 2 and 3 Clinical Trials with Novel Therapies in MASH Cirrhosis: A Systematic Review
     Grzegorz Zurakowski, Anna Wiela−Hojeńska, Paweł Wojciech Petryszyn · 2026 · Journal of Clinical Medicine